BDA-366-induced robust apoptosis in primary myeloma cells from untreated patients or patients with relapsed/refractory myeloma with varying genetic background further indicates that BDA-366 as a novel BCL2 BH4 antagonist possesses potent therapeutic effect for relapsed/refractory myeloma. This evidence concerns the gene BCL2 and plasma cell myeloma.